Related Experiment Videos
Adverse reactions to intravenous codeine phosphate in children. A report of three cases
Insights
Intravenous codeine phosphate caused severe adverse reactions, including hypotension and apnoea, in three children. These findings support avoiding intravenous codeine phosphate in pediatric patients.
Area of Science:
- Pediatric Pharmacology
- Adverse Drug Reactions
- Clinical Toxicology
Background:
- Codeine phosphate is commonly used for pain management.
- Parenteral administration routes require careful consideration due to potential for rapid systemic effects.
- Existing literature and formularies provide limited guidance on intravenous codeine phosphate use in children.
Observation:
- Three pediatric patients experienced severe adverse events following intravenous codeine phosphate administration.
- Observed reactions included tachycardia, cutaneous vasodilatation, severe hypotension, and apnoea.
- These events highlight a significant risk associated with this route of administration in the pediatric population.
Findings:
- The study identified a direct correlation between intravenous codeine phosphate and serious adverse reactions in children.
- A review of medical literature and pharmacopeias revealed inadequate information regarding the safe parenteral use of codeine phosphate.
- The observed cases strongly suggest that intravenous codeine phosphate is not suitable for pediatric use.
Implications:
- Clinical guidelines and drug formularies should be updated to reflect the risks of intravenous codeine phosphate in children.
- Healthcare providers should exercise extreme caution and consider alternative analgesics for pediatric patients.
- Further research into the pharmacokinetics and pharmacodynamics of codeine in pediatric populations may be warranted.
Abstract:
Adverse reactions ranging from tachycardia and cutaneous vasodilatation to severe hypotension and apnoea occurred in three children who were given codeine phosphate intravenously. The cause of these reactions is discussed and a review of the literature on the parenteral use of codeine phosphate is presented. The findings indicate that the standard reference formularies and pharmacopeoiae, with one exception, deal inadequately with the parenteral use of codeine phosphate. On the evidence of the cases presented we would support the conclusion of the American Medical Association's drug evaluations, that codeine phosphate should not be used intravenously in children.